Red blood cell transfusion triggers and transfusion alternatives in elective orthopedic hip and knee replacement surgery – a review

Abstract: In elective hip and knee replacement surgery, the use of red blood cell transfusion alternatives has been widely accepted. However, nowadays, more evidence is accumulating that suggests some transfusion alternatives may no longer be cost effective. In this review, an evidence-based overview of the applied transfusion alternatives is provided, aiming for optimal and cost-effective patient blood management in elective hip and knee replacement surgery.

Keywords: patient blood management, erythropoietin, autologous blood, cell salvage

Introduction

Total hip and knee prosthesis surgery is performed worldwide approximately two million times annually and approximately 50,000 in the Netherlands. These surgeries may result in significant intra- and postoperative blood loss (800–1,500 mL), with a potential need for allogeneic red blood cell (RBC) transfusions to compensate for the resulting anemia. Although blood transfusions are relatively safe, transfusion reactions, such as fever, hemolysis, antibody formation, transfusion-associated cardiac overload (TACO), transfusion-related acute lung injury (TRALI), or transmission of infectious agents may occur. Furthermore, natural killer (NK) activity may be decreased in patients after an allogeneic RBC transfusion compared with no RBC transfusion or with autologous blood reinfusion. It has been postulated that due to immunomodulatory effects, allogeneic blood transfusions may result in an increased susceptibility to infections in the postoperative period. In the field of orthopedic surgery, as well as in other disciplines, there is an ongoing trend to aim for optimal patient blood management (PBM). PBM has been introduced in Transfusion Medicine as an evidence-based best practice that is based on three approaches (pillars): 1) optimizing the patient’s own blood; 2) minimizing surgical blood loss and bleeding; and 3) harnessing and optimizing the patient-specific physiological reserve to compensate for anemia (including restrictive transfusion thresholds).

This approach includes not only preoperative, intraoperative, and postoperative strategies for managing the patient, such as alternatives for RBC transfusions, but also surgical and anesthesiological strategies. A comprehensive overview of blood conservation strategies in major orthopedic surgery in the European setting was presented by Muñoz et al. In a more recent review, Ponnusamy et al discussed the potential complications of blood transfusions in orthopedic surgery patients and discussed the use of restrictive transfusion thresholds as a strategy to lower the need for RBC transfusions. It was suggested that RBC transfusions may place patients at greater risk for

Cynthia So-Osman
Department of Transfusion Medicine, Sanquin Blood Supply, Leiden, the Netherlands

Correspondence: Cynthia So-Osman
Department of Transfusion Medicine, Sanquin Blood Supply, Plesmanlaan 1a, 2333 BZ Leiden, the Netherlands
Tel +317 1568 5136
Fax +317 1568 5191
Email c.so@sanquin.nl
infections, including surgical site infections, which can be decreased by using a restrictive transfusion policy.11

In this review, an evidence-based overview is provided of the applied transfusion alternatives aiming for optimal and cost-effective PBM in elective hip and knee replacement surgery.

Transfusion practice
A large variation in transfusion policy among countries and even among hospitals within a country can still be seen as common practice. In the first Austrian benchmark study, Gombotz et al found a transfusion rate varying from 16%–85% for patients undergoing primary total hip replacement and a 12%–87% transfusion rate for patients undergoing primary total knee replacement surgery.12 In the second benchmark study, which was published recently, transfusion rates have decreased in total hip replacement (from 41% to 30%) and total knee replacement (41%–25%), however, with still substantial between-center variability.13 These studies show that the implementation of guidelines in daily practice is difficult. This is relevant, not only for implementing transfusion thresholds but also, for the number of transfusions at each event to reach a particular target hemoglobin (Hb) level. Barr et al investigated RBC transfusion practice in Northern Ireland in 2005 and still found a two-unit instead of single-unit transfusion practice in medical and surgery patients (n=1,474).14

Blood transfusion threshold protocols
Within the strategy of PBM, the use of a restrictive blood transfusion protocol can be regarded as an important blood-saving and cost-saving strategy. In 1988, the National Institutes of Health (NIH) published consensus guidelines for RBC transfusions.15 Since then, several guidelines have been published, recommending that a range of Hb levels between 6 and 10 g/dL can be used, depending on the presence of serious comorbidity.16–18 These clinical practice guidelines, however, have based their recommendations on data from published reports on series of patients for whom RBC transfusions were withheld (for instance Jehovah’s witnesses) and observational studies, rather than on the results of clinical trials. Since June 2004, the 4-5-6 Flexinorm transfusion trigger (Hb values in mmol/L), based on the NIH guidelines, in the surgical setting has been recommended in the Dutch national consensus guideline for blood transfusion. This transfusion trigger policy is based on parameters as Hb level, age, and condition of the patient (American Society of Anesthesiologists [ASA criteria]). In 2012, an updated systematic review from Carson et al19 showed that restrictive transfusion strategies lowered the RBC transfusion risk by 39% (relative risk [RR] = 0.61; 95% confidence interval [CI]: 0.52 to 0.72) and the mean transfusion rate by 1.19 units (95% CI: 0.53 to 1.85 units). However, heterogeneity between the studies was high (P<0.00001; I²>93%) for these outcomes, and in some papers, the methodological quality was unclear. By using a restrictive transfusion strategy, postoperative complication rate was neither different from using a liberal transfusion strategy (ie, mortality and cardiovascular complications, such as myocardial infarction and stroke, pneumonia, and thromboembolic complications), nor was functional recovery, or hospital or intensive care length of stay. However, hospital mortality was significantly reduced in the groups with a restrictive transfusion strategy (RR = 0.77; 95% CI: 0.62 to 0.95) but 30 day mortality was not (RR = 0.85; 95% CI: 0.70 to 1.03). In this review, the results of the FOCUS trial was included, which randomized only patients with a positive cardiovascular history.19 The authors concluded that the existing evidence supported the use of restrictive transfusion triggers in the majority of patients, including patients with a cardiovascular history.20

A recent systematic review focused on the effect of transfusion thresholds on postoperative infection rate and concluded that restrictive transfusion thresholds lowered infection risk.21

The addition of single-unit transfusion policies have been investigated in several observational studies: A 25% reduction in RBC transfusions was found in hematological patients receiving intensive chemotherapy or stem cell transplantation.22 Observational studies in (orthopedic) surgery patients that implemented a single-unit policy next to a restrictive transfusion policy may lead to a larger reduction in RBC use.23–25

Current alternatives for allogeneic RBC transfusions
Many alternatives for allogeneic RBC transfusion are available. Not all interventions are widely applied. Next to efficacy, important factors that are of influence are costs, user friendliness, and safety. Based on randomized controlled studies, the efficacy of the different modalities will be discussed. The modalities of tourniquet use or acute hypervolemic hemodilution are regarded as being standard practice and are therefore not discussed here. The alternatives for allogeneic blood transfusion can be subdivided in
two main groups: nonpharmacotherapeutic (group A) and pharmacotherapeutic interventions (group B) (Table 1).

### Current evidence on transfusion alternatives in elective hip and knee replacement surgery patients

#### Nonpharmacotherapeutic interventions

#### Preoperative autologous donation (PAD)

Five trials reported on orthopedic surgery patients (n=425) and showed a significant transfusion avoidance of 79%. However, autologous orthopedic donors were more likely to have an increased overall transfusion rate with allogeneic and/or autologous blood (odds ratio [OR] =1.78; 95% CI: 0.61 to 5.20). The use of PAD is relatively expensive and complex and needs a fixed surgery date (the patient needs to visit the blood center several times to donate blood). In addition, the likelihood for mistakes by switching of blood products is high. The British guidelines only advise PAD in exceptional cases if the normal donor stock is insufficient, as in cases of rare blood group typing and/or antibodies against public antigens et cetera.

#### Acute normovolemic hemodilution (ANH)

Three systematic reviews reported on the use of ANH in six and 13 orthopedic trials, respectively. Both did not report a significant benefit of ANH for transfusion avoidance. Compared with another blood-sparing modality (PAD or tranexamic acid [TXA]), ANH was less effective in orthopedic patients. As a transfusion alternative, ANH is therefore not recommended in knee and hip surgery.

#### Perioperative alternatives

#### Autologous reinfusion (cell saver and postoperative reinfusion systems)

In a Cochrane review evaluating all randomized studies up to 1 June 2009 in which the effect on RBC use of washed shed blood (by means of cell saver) or unwashed shed blood by means of postoperative reinfusion systems, 36 studies reported on orthopedic surgery. The authors concluded a significant transfusion avoidance of 54% and a significant mean RBC-sparing of 0.82 RBC units/patient as well. The outcomes were similar using washed or unwashed blood. The authors, however, concluded that the methodological quality was poor and that the findings could have been influenced by bias. There was a lack of concealment, meaning that allocation of the randomization was not centralized but often, on location, by drawing an opaque envelope. This method can be susceptible to bias because it cannot be confirmed that the envelopes are drawn in the proper order. In an updated systematic review (van Bodegom-Vos et al) that included all randomized controlled studies until January 2013, a time effect was found, including that studies published from 2010 onward resulted in a loss of blood-sparing effect of autologous reinfusion in both knee and hip replacement surgeries. This could be explained by the use of restrictive transfusion thresholds in the later studies.

#### Pharmacotherapeutic interventions

#### Interventions to increase the preoperative Hb level

<table>
<thead>
<tr>
<th>Table 1 Red blood cell transfusion alternatives (group A and group B)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group A: nonpharmacotherapeutic interventions</strong></td>
</tr>
<tr>
<td>1. Preoperative alternatives</td>
</tr>
<tr>
<td>• PAD[26,28]</td>
</tr>
<tr>
<td>2. Perioperative alternatives</td>
</tr>
<tr>
<td>• ANH, in which one or several units of whole blood is taken just before surgery and at the same time (= normovolemic), the lost blood volume is replaced by normal saline or colloids. The retained whole blood is then transfused back to the patient during or after surgery[29,30]</td>
</tr>
<tr>
<td>• Use of the cell saver, which collects autologous wound blood during (and sometimes after) surgery. The shed blood is washed, concentrated, and then reinfused[31,33]</td>
</tr>
<tr>
<td>3. Postoperative alternatives</td>
</tr>
<tr>
<td>• Devices that collect and reinfuse autologous wound blood after surgery (unwashed, filtered by several types of devices)[31,33]</td>
</tr>
<tr>
<td><strong>Group B: pharmacotherapeutic interventions</strong></td>
</tr>
<tr>
<td>1. To increase preoperative hemoglobin level</td>
</tr>
<tr>
<td>• The preoperative use of Epo[30-34,42] and the preoperative use of (intravenous) iron[31-34]</td>
</tr>
<tr>
<td>2. To reduce perioperative blood loss</td>
</tr>
<tr>
<td>• The perioperative use of antifibrinolytics, eg, aprotinin, tranexamic acid, and fibrin glue[34,79]</td>
</tr>
</tbody>
</table>

**Abbreviations:** ANH, acute normovolemic hemodilution; Epo, erythropoietin; PAD, preoperative autologous donation.
Intravenous (IV) iron

Anemia increases with age, with an overall prevalence of 11% in males and 10% in females older than 65 years, if defined according to the World Health Organization (WHO) criteria.41-44 One-third can be explained by nutritional causes (of which half are due to iron deficiency), one-third by anemia of chronic disease, and unexplained anemia in the remaining one-third of patients. These latter two categories of patients are characterized by low Epo levels and low levels of proinflammatory cytokines.45,46

If anemia is due to nutritional causes, correction might be easily performed by supplementing the deficient components. However, if anemia is due to anemia of chronic disease or unexplained anemia, it may be necessary to find the underlying disease that causes the anemia (e.g., kidney failure or malignancy). If a patient is then still eligible for elective surgery, preoperative measures to increase the Hb level can be considered.

Since the preoperative Hb level was consistently reported as an independent significant risk factor for a RBC transfusion, it was included in the workup for optimizing perioperative PBM.47,48 A PBM protocol was developed by a Network for Advancement of Tranfusion Alternatives (NATA) working party aiming for preoperative nonanemic levels in the elective orthopedic surgery population. In this specific population, 14.1% suffer from preoperative anemia.49 Due to the elective character, the optimal preoperative treatment can be explored. Use of Epo (combined with oral iron) to increase Hb to normal levels is very costly. A less costly alternative may be the use of IV iron, since IV iron therapy may increase Hb values, not only in iron-deficient patients but also, in patients with anemia of chronic disease, bypassing the blocking effect of hepcidin that makes iron unavailable for incorporation in RBCs.50 Whether patients with unexplained anemia benefit from either IV iron or Epo therapy, or are refractory to both treatments, is unknown and must be further evaluated.

The efficacy and safety of IV iron compared with oral iron or to placebo was studied in several randomized trials and was reported in a systematic review.51 In that review, IV iron significantly increased Hb levels compared with placebo and oral iron. Furthermore, the use of IV iron was safe.

In orthopedic surgery, no randomized trials have been published that primarily evaluated the use of IV iron as a transfusion alternative and compared its effect with other blood management modalities. However, in hip fracture surgery, a randomized pilot study showed that transfusion requirements in patients with intracapsular fracture or baseline Hb level of 12 g/dL or more appear to be reduced by IV iron therapy, without any difference in morbidity, mortality, or length of hospital stay.52 Other randomized studies are currently underway.53,54

Interventions to reduce perioperative blood loss

Antifibrinolytics

Since trials on antifibrinolytics comprised mostly cardiac surgery patients, who differ from orthopedic surgery patients, outcome for RBC use may also be quite different between these two study populations. The results of trials of the orthopedic surgery population are discussed here.

Interventional drug versus control group

Aprotinin

In a meta-analysis involving 18 randomized controlled trials (1,276 major orthopedic surgery patients), Huang et al found that aprotinin led to a significant reduction in transfusion requirements (RR = 0.59; 95% CI: 0.51 to 0.69). The use of aprotinin significantly reduced total blood loss by a mean of
498.88 mL (95% CI: −735.03 to −262.72) and the number of blood transfusions per patient by 0.93 units (95% CI: −1.36 to −0.51), without an increase in the risk of deep vein thrombosis (DVT) (RR = 0.58; 95% CI: 0.38 to 1.08).53

After a study in cardiac surgery patients (the BART study) showed that aprotinin was significantly associated with increased mortality compared with TXA and epislon amino caproic acid (EACA), the use was prohibited.56 Nowadays, more and more data is accumulating in favor of aprotinin.57,58 Following its withdrawal in 2007, the regulators now license aprotinin for myocardial revascularisation only, which is at relatively low risk for bleeding.59

TXA
A meta-analysis on the use of TXA compared with controls reported a total of 46 randomized controlled trials involving 2,925 patients. The use of TXA significantly reduced total blood loss by a mean of 408.33 mL (95% CI: −505.69 to −310.77) and the number of blood transfusions per patient by 0.78 units (95% CI: −0.19 to −0.37). TXA led to a significant reduction in transfusion requirements (RR = 0.51; 95% CI: 0.46 to 0.56) and no increase in the risk of DVT (RR = 1.11; 95% CI: 0.69 to 1.79). The authors concluded that TXA significantly reduced blood loss and blood transfusion requirements in patients undergoing orthopedic surgery and did not appear to increase the risk of thromboembolic events.60 However, others discussed that its safety remains uncertain and that this needs to be the subject of future research.61,62

EACA
A meta-analysis reported 16 trials of EACA compared with controls, four trials involved orthopedic surgery (n=304 patients) in which the use of EACA did not reduce the need for allogeneic RBC transfusions. Two trials reported a marginally effective reduction in total blood loss of 300 mL (mean difference 95% CI: 77 to 523). Mortality risk, risk of myocardial infarction, and thrombotic events were not increased.63

Comparison among antifibrinolytics
Aprotinin versus TXA
Of 21 trials on aprotinin versus TXA that reported data on the number of patients exposed to allogeneic RBC transfusions, only one study64 was performed in orthopedic surgery patients (knee replacement surgery [n=36]). The study size consisted of three groups of 12 patients (controls versus TXA versus aprotinin, respectively) and showed no difference in the transfusion rate between all three groups. No adverse outcomes were reported other than DVTs (n=2 in the TXA group, n=1 in aprotinin group, and n=0 in control group).63

Aprotinin versus EACA
Of 12 reported trials, three (reported by Amar et al65 on spinal surgery [n=69], by Ray et al66 on hip surgery [n=45], and by Urban et al67 on spinal surgery [n=60]) investigated orthopedic surgery patients: no significant transfusion avoidance was found with aprotinin compared with EACA (RR = 0.82; 95% CI: 0.48 to 1.40).65-67 The RR, however, was comparable with the risk in cardiac surgery patients, in which a significant transfusion avoidance with aprotinin was found (RR = 0.82; 95% CI: 0.76 to 0.89). Ray et al performed a study on 45 total hip arthroplasty patients66 and did not find a difference in blood loss between aprotinin and EACA (for each, there were 15 patients per group) or in mean RBC reduction or transfusion avoidance.

Pooled data on adverse events (myocardial infarction and thrombotic events) showed no difference between the study and control groups. In the single-hip surgery trial of Ray et al,66 no thrombotic events, such as DVT or pulmonary embolism were found. Six cardiac adverse events were reported post-operatively in the intervention groups: two non-ST elevation myocardial infarction, two atrial fibrillation, and two patients with both myocardial infarction and atrial fibrillation; however, this did not reach statistical significance compared with the control group in these 45 patients (P=0.08).63

TXA versus EACA
Of eight reported trials (n=2,003), only one orthopedic study (knee replacement surgery [n=127]) compared TXA (n=35) with EACA (n=32) and placebo (n=60), and found no difference in blood loss between TXA and EACA or in transfusion avoidance, mean RBC reduction, or adverse events.68

Fibrin glue
Fibrin glue generally consists of two major components, fibrinogen and thrombin, which when applied to wound surfaces, helps to stop the bleeding. This sealant can be prepared from allogeneic or from autologous blood. The glue is generally sprayed directly onto wound surfaces during surgery in order to reduce blood loss and therefore, may avoid blood transfusions. Carless et al concluded, in a Cochrane review, that especially in orthopedic surgery, where blood loss is often substantial, fibrin sealants appear to demonstrate their greatest beneficial effects by significantly reducing blood loss and transfusion by 32% (RR = 0.68; 95% CI: 0.51 to 0.89), but large randomized controlled trials were lacking.69 An updated
Discussion and concluding remarks

Since the frequency of knee and hip replacement surgery is exponentially growing, expecting a twofold increase from 50,000 to more than 100,000 arthroplasties in 2030 in the Netherlands,1 optimizing perioperative blood management is not only highly relevant with respect to patient risks and benefits but also, important in terms of cost effectiveness. Although RBC transfusion alternatives are widely available, nowadays, more and more evidence is accumulating that shows some transfusion alternatives may no longer be cost effective for the general elective hip or knee replacement surgery patient. In the perspective of PBM, the first and most cost-effective blood-sparing modality will be the implementation of a restrictive transfusion threshold, including a single-unit transfusion policy. Compared with controls, the antifibrinolytic agents aprotinin and TXA resulted in significant transfusion avoidance. Due to its low costs and its safe use, TXA can be used as an acceptable modality, in addition to a restrictive transfusion policy, to lower blood use. In systematic reviews, the use of PAD, ANH, and cell salvage have lost their value as transfusion alternatives. The role of fibrin glue has not yet been established. Epo remains as a blood-sparing alternative, however, at unacceptably high costs. Nowadays, the PBM focus has shifted to the preoperative anemic patient, who can be regarded as a patient at risk for a RBC transfusion, for which IV iron may be an acceptable transfusion alternative. However, more studies are needed to make definite conclusions on this modality. Overall, for all potential transfusion alternatives, the costs and safety associated with its use should always be weighed against the benefits.

Disclosure

The author reports no conflicts of interest in this work.

References


43. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011;11(4).


